UA138925U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes clinical examination, radiography. Additionally, in the patient's serum determine the polymorphism of methylenetetrahydrofolate reductase genes (MTHFR C677T), nitric oxide synthase (eNOS T786C), the content of endothelin, folic acid, pyridinoline, transforming growth factor beta 1 (6) and лей-β homozygous carrier 677-TT, 786-CC and endothelin levels> 10 ng / ml, folic acid <6 ng / ml, pyridinoline> 8 ng / ml, ΤΦΡ-β1 <14 ng / ml, IL-6> 10 ng / l predict the development of osteoarthritis.

Description

The proposed useful model The method of predicting the development of osteoarthritis belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in diagnosing the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (Okorokov

A.N. Diagnosis of diseases of internal organs. - M., 2001. - T. 2. - E. 186-196). The disadvantage of these methods is the lack of an opportunity to predict the dynamics of the process in the early subclinical stages, to prevent its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The set task is solved by the fact that, in addition to clinical examination and radiography, polymorphism of methylenetetrahydrofolate reductase genes (MTNEV) is determined in the patient's blood serum

Сб677Т), nitric oxide synthase (ЕЕМО5 1786С), the content of endothelin, folic acid, pyridinoline, transforming growth factor beta 1 (TGF-VDI), interleukin 6 (IL-6). With homozygous carrier 677-TT, 786-SS, levels of endothelin 210 ng/ml, folic acid "6 ng/ml, pyridinoline "8 ng/ml, TGF-DVI "14 ng/ml, IL-6 210 ng/l are predicted development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, x-rays are taken, the polymorphism of MTNEV C677T, eMmo5 T786C genes is determined, the content of endothelin, folic acid, pyridinoline, TFR-VI, IL-6 is determined by the immunoenzymatic method. With homozygous carrier 677-177, 786-SS, levels of endothelin 210 ng/ml, folic acid "6 ng/ml, pyridinoline 28 ng/ml, TFR-DI1 -14 ng/ml, IL-6 "10 ng/l are predicted development of osteoarthritis.

A specific example of using the method

Patient V., 59 years old, was hospitalized in the clinic due to pain syndrome in the right knee joint. Examined, X-ray taken. No signs of osteoarthritis were found. The polymorphism of MTNEV S677T and emo5 17860 genes was determined in blood serum. The content of endothelin, folic acid, pyridinoline, TFR-VI, and IL-6 was determined by immunoenzymatic method. A homozygous carrier of 677-TT and 786-SS was established, the levels of endothelin - 20 ng/ml, folic acid - 3.8 ng/ml, pyridinoline - 14 ng/ml, TGF-B1-7.5 ng/ml, IL-6 -22 ng/l. Diagnosed development

From osteoarthritis. After 11 months, X-rays showed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that in addition, polymorphisms of methylenetetrahydrofolate reductase (MTNEV C677T), nitric oxide synthase (EMO5 1786C), content of endothelin, folic acid, pyridinoline, transforming growth factor beta 1 (TGF-DI1), interleukin 6 (IL -b) and with homozygous carriers of 677-TT, 786-SS and endothelin levels of 210 ng/ml, folic acid "6 ng/ml, pyridinoline "8 ng/ml, TFR-B1 "14 ng/ml, IL-6 "10 ng/l predict the development of osteoarthritis.